Circassia Pharmaceuticals PLC (CIR) Receives "Buy" Rating from Numis Securities Ltd

Circassia Pharmaceuticals Plc

Circassia Pharmaceuticals Plc

The stock of Circassia Pharmaceuticals PLC (LON:CIR) has "Buy" rating given on Monday, March 14 by Numis Securities. This represents a dividend yield of 0.78%.

Hikma Pharmaceuticals Plc is a pharmaceutical company.

Jefferies Group LLC raised their target price on Hikma Pharmaceuticals Plc from GBX 2,000 ($24.84) to GBX 2,065 ($25.64) and gave the company a buy rating in a research note on Thursday, December 15th. RBC Capital Markets maintained Circassia Pharmaceuticals PLC (LON:CIR) on Friday, April 1 with "Top Pick" rating. Three analysts have rated the stock with a hold rating and three have issued a buy rating to the stock. Hikma Pharmaceuticals Plc now has a consensus rating of Buy and an average target price of GBX 2,373.30 ($29.47). Peel Hunt maintained the shares of CIR in report on Wednesday, November 25 with "Buy" rating. (Frankfort First Bancorp). It has a 72.54 P/E ratio. The Firm operates through three divisions: Allergy, which relates to a range of immunotherapy development products for the treatment of allergy; NIOX, which relates to the portfolio of products used to improve asthma diagnosis and management by measuring fractional exhaled nitric oxide, and Respiratory, which relates to the portfolio of asthma and chronic obstructive pulmonary disease product candidates.

Investors sentiment decreased to 0.67 in 2016 Q4.

In analysts report shared with investors on 25 April, Circassia Pharmaceuticals Plc (LON:CIR) stock had its Hold Rating reiterated by professional analysts at Cantor Fitzgerald.

Circassia Pharmaceuticals has 284,889,000 shares outstanding at the moment which are trading around 100.09 bringing Circassia Pharmaceuticals's market capitalisation to 285.14M GBP. The firm has "Buy" rating by Peel Hunt given on Wednesday, May 25. As per Tuesday, September 27, the company rating was reinitiated by Numis Securities. The rating was maintained by Cantor Fitzgerald on Friday, March 17 with "Hold". This is a boost from Hikma Pharmaceuticals Plc's previous dividend of $0.21. Principal Gp holds 0.01% or 120,460 shares in its portfolio. The rating was maintained by JP Morgan on Monday, March 20 with "Neutral".

Since November 11, 2016, it had 0 insider buys, and 4 sales for $312,815 activity. It now has negative earnings. The Company's segments include Branded, Injectables, Generics and Others. The California-based Blackrock Fund Advsrs has invested 0.02% in Circassia Pharmaceuticals PLC (LON:CIR). Its next-generation immunotherapy is in Phase III testing for cat allergy.

Receive Circassia Pharmaceuticals News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Circassia Pharmaceuticals with MarketBeat.com's FREE daily email newsletter.